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Objectives This study investigated the effect of bariatric surgery (BS)–induced weight loss on cardiac ectopic fat using 3T
magnetic resonance imaging in morbid obesity.
Background Heart disease is one of the leading causes of mortality and morbidity in obese patients. Deposition of cardiac
ectopic fat has been related to increased heart risk. Whether sustained weight loss can modulate epicardial fat
or myocardial fat is unknown.
Methods Twenty-three morbidly obese patients underwent 1H-magnetic resonance spectroscopy to determine myocardial
triglyceride content (MTGC), magnetic resonance imaging to assess epicardial fat volume (EFV), cardiac function,
and computed tomography visceral abdominal fat (VAF) measurements at baseline and 6 months after BS.
Results The BS reduced body mass index significantly, from 43.1  4.5 kg/m2 to 32.3  4.0 kg/m2, subcutaneous fat
from 649  162 cm2 to 442  127 cm2, VAF from 190 83 cm2 to 107  44 cm2, and EFV from 137 37 ml to
98  25 ml (all p  0.0001). There was no significant change in MTGC: 1.03  0.2% versus 1.1  0.2%
(p  0.85). A significant reduction in left ventricular mass (118  24 g vs. 101  18 g) and cardiac output
(7.1  1.6 l/min vs. 5.4  1.0 l/min) was observed and was statistically associated with weight loss (p  0.05).
The loss in EFV was limited (27  11%) compared to VAF diminution (40  19%). The EFV variation was not
correlated with percentage of body mass index or VAF loss (p  0.007). The ratio of %EFV to %VAF loss de-
creased with sleep apnea syndrome (1.34  0.3 vs. 0.52  0.08, p  0.05).
Conclusions Six-month BS modulates differently cardiac ectopic fat deposition, with a significant decrease in epicardial fat
and no change in myocardial fat. Epicardial fat volume loss was limited in patients with sleep apnea. (Impact of
Bariatric Surgery on Epicardial Adipose Tissue and on Myocardial Function; NCT01284816) (J Am Coll Cardiol
2012;60:1381–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.016Accumulation of ectopic fat, including visceral obesity, has
been recognized recently to be a consequence of adipose
tissue (AT) dysfunction and the inability of subcutaneous
AT to store excess triglycerides with weight gain (1,2).
ardiac ectopic fat includes visceral depots surrounding the
eart, epicardial fat (Efat), which is located between the
myocardium and visceral layer of the pericardium, and
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cardiomyocytes may lead to lipotoxicity of the myocardium
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Bariatric Surgery and Cardiac Ectopic Fat October 9, 2012:1381–9and has a deleterious effect on
left ventricular (LV) function
(5,6). However, whether sus-
tained weight loss induced by
bariatric surgery (BS) can modu-
late myocardial triglyceride con-
tent (MTGC) is unknown. Epi-
cardial fat is an ectopic fat
deposit surrounding the myocar-
dium and coronary arteries with-
out any separation between the
cardiomyocytes or adventitia (7).
Epicardial adipose tissue (EAT)
has been shown to release para-
crinally bioactive molecules, such
as inflammatory mediators, adi-
pocytokines, and free fatty acids,
which pass through the coronary
wall by diffusion, from outside
to inside, and interact with the vascular cells (8,9).
Increased amounts of EAT have been shown in obese and
diabetic patients (10). Epicardial adipose tissue strongly
associates with accumulation of visceral abdominal fat
(VAF). Due to its particular anatomical location and its
proximity to coronary arteries, Efat has been further linked
ith coronaropathy: patients with coronary artery disease
CAD) accumulate more Efat than patients without CAD
(11–14). An increase in Efat has also been associated with an
early decrease in coronary microvascular response (15),
suggesting its possible early contribution to the initiation of
atherosclerosis and to obesity-related cardiac complications.
Few studies have assessed the effect of nutritional inter-
ventions on Efat (16–18). One study evaluated the effect of
BS on epicardial fat thickness, but was limited by the
2-dimensional assessment of echocardiography (18). Mag-
netic resonance imaging (MRI) is a noninvasive technique
previously validated in studies of severe obesity to accurately
quantify epicardial fat volume (EFV). Proton magnetic
resonance spectroscopy has also been used in the past to
assess MTGC (19–21). Bariatric surgery has been demon-
strated to induce important weight loss in obese patients
and to reduce cardiovascular mortality and cardiovascular
events by 50% in patients with severe obesity (22). However,
its effect on cardiac ectopic fat deposition has been scarcely
investigated and is debated.
This study examines the effects of substantial weight loss by
severely obese patients at 6 months after bariatric surgery on
EFV, MTGC content, LV volumes, ejection fraction, and
mass using 3-T MRI and magnetic resonance spectroscopy.
Methods
Subjects. Between October 2010 and November 2011, 70
subjects were eligible to be enrolled in the study and 29
patients were included to undergo BS for severe obesity
Abbreviations
and Acronyms
AT  adipose tissue
BMI  body mass index
BS  bariatric surgery
EAT  epicardial adipose
tissue
Efat  epicardial fat
EFV  epicardial fat
volume
LV  left ventricular
MRI  magnetic resonance
imaging
MTGC  myocardial
triglyceride content
VAF  visceral abdominal
fat(mean body mass index [BMI] 43.1  4.5 kg/m2) (OnlineAppendix, Online Fig. 1). Patients were recruited for
standard indications: BMI 40 or BMI 35 kg/m2 plus an
dditional comorbidity, and volunteered to undergo cardiac
RI before and at 6 months after surgery. All subjects were
creened for cardiovascular risk factors and for obesity-
elated metabolic and respiratory complications, and had a
etailed physical examination. Patients 18 years or 65
years of age or with cardiac, renal, or hepatic failure, poorly
controlled diabetes mellitus, hypertension, neoplastic dis-
eases, and major psychiatric disorders or unstable eating
disorders were excluded from this study (Online Fig. 1). All
subjects had a normal 12-lead electrocardiogram, and nor-
mal global and regional resting cardiac function assessed by
transthoracic echocardiography. Stress test or thallium myo-
cardial scintigraphy with exercise testing or dipyridamole
injection allowed us to exclude patients with CAD (or stress
echocardiography with dobutamine injection in case of
contraindication). Four patients were excluded because of
obesity-related dilated cardiomyopathy (n  2), or CAD
(n  2). No diabetic patient was taking thiazolinediones or
nsulin agents known to modulate intracellular lipid content.
egular physical activity was encouraged (3 h to 5 h weekly
aximum), but none of the subjects engaged in high-
erformance sports. Sleep apnea syndrome (SAS) was as-
essed using a polysomnography, which was performed with
ontinuous recording of electroencephalogram, electroocu-
ogram, nasal airflow, body position, thoracic and abdomi-
al respiratory efforts, and arterial oxyhemoglobin saturation
SaO2) recorded by a pulse oxymeter. Apnea was defined as
the cessation of airflow for at least 10 s; a decrease in
ventilation 50% that lasted at least 10 s associated with a
SaO2 reduction of at least 4% defined hypopnea. An average
number of apnea and hypopnea per hour of sleep (apnea-
hypopnea index) 15 defined the SAS group.
The study was approved by the local ethics committee, and
informed written consent was obtained from each patient.
Blood tests. Fasting blood tests for glucose, including an
oral glucose tolerance test, cholesterol, insulin, hemoglobin
A1c, fibrinogen, C-reactive protein, and plasminogen-
activator inhibitor (PAI)-1, were taken at baseline and at 6
months. Plasmatic total adiponectin was determined by
enzyme-linked immunosorbent assay (Quantikine Human
Adiponectin, R&D Systems, Minneapolis, Minnesota), and
serum leptin levels were measured using a commercially
available enzyme-linked immunoassay kit (SPI-BIO, Ber-
tin, France). An estimate of insulin resistance was calculated
using the homeostasis model assessment of insulin resis-
tance (HOMA-IR) equation (fasting plasma insulin [U/ml]
times fasting glucose [mmol/l] divided by 22.5).
Abdominal computed tomography scan, anthropometric
measurements, and percentage excess weight loss. A
single breath hold, 10-slice computed tomography scan
centered on the fifth lumbar vertebra was acquired. Images
were manually contoured for visceral fat adipose tissue
quantification. Anthropometrics (body weight, BMI, and
waist, hip, and thigh circumferences) were measured at
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October 9, 2012:1381–9 Bariatric Surgery and Cardiac Ectopic Fatbaseline and after 6 months of weight loss. Percentage losses
were calculated according to the following formula: percentage
of parameter loss  (parameter before surgery minus param-
eter after surgery divided by parameter before)  100. The
atio of %EFV loss to %VAF loss was calculated to search for
actors that predicted limited EFV loss compared to VAF loss
ratio 1, when %EFV loss was less than %VAF loss).
ardiovascular magnetic resonance imaging. The cardio-
ascular magnetic resonance imaging was performed on a 3-T
ide-bore magnet (Verio, Siemens Medical Solutions, Erlan-
en, Germany) equipped with a 32-element phased array coil.
ine sequences. Cardiac structural and functional data
ere assessed using a multislice steady-state free precession
ine sequence in short-axis view that covered the LV from
ase to the apex with the following parameters: field of
iew 340 340 mm2, echo time TE 1.2 ms, repetition
time TR  61 ms, matrix  134  192, slice thickness 
6 mm, 4-fold GRAPPA k-space reduction, as previously
described (10). Dedicated post-processing software (Argus,
Siemens Medical Solutions) was used to measure LV mass,
cardiac output, stroke volume, end-diastolic volume, and
end-systolic volume, and to calculate left ventricular ejection
fraction (LVEF). Left ventricular mass and cardiac output
were indexed to body surface area, LV mass index, and
cardiac index to enable more stringent allowance for obesity.
Figure 1 Different Images Acquisition
Different images acquisition and after treatment showing (A) the contouring of ep
(C) a phase contrast image at the level of the mitral valve, and (D) the transmitraMitral flow velocity-encoded imaging. During short
breath holds, quantitative flow images were acquired with a
prospectively gated velocity-encoding cardiovascular mag-
netic resonance imaging technique (slice thickness  5.5
mm, TE  1.98 ms, TR  47.50 ms, field of view  320
m, 20 phases per RR interval). These acquisitions were
one in planes oriented parallel to the mitral valve plane,
nd positioned at a distance of 1.5 cm from the valve plane
oward the apex. The early (E) and late (A) peak diastolic
ransmitral flow velocities were calculated with an Argus
orkstation for quantitative flow analysis (Fig. 1) (23). Left
trial area (cm2) was manually contoured following the
endocardium on a 4-chamber cine view, just before mitral
valve opening, with manual planimetry (24).
Epicardial fat volume. Epicardial fat included only fat
between the epicardial layer and internal visceral layer of the
pericardium. The border between epicardial and pericardial
fat was localized by visual inspection of the entire cine series
in all slices. Areas of Efat were then traced manually on
consecutive end-systolic short-axis images, beginning at the
mitral valve and ending at the last slice containing cardiac
adipose tissue, as previously described (Fig. 1) (10). The
areas obtained for each slice were summed together and
multiplied by the slice thickness to yield EFV. Intraobserver
and interobserver reproducibility of EFV was excellent, with
variations of coefficient of 1.9% and 4.5%, respectively.
l fat, (B) an example of cardiac proton spectroscopy,
flow profile.icardia
l blood
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Bariatric Surgery and Cardiac Ectopic Fat October 9, 2012:1381–9Consistency between measurements at follow-up (i.e., at
6 months) was obtained by individual anatomical land-
marks and by using the same imaging parameters. More-
over, EFV measurement at baseline and 6 months was
done on the same screen and at the same time to
superpose slice level.
Proton magnetic resonance spectroscopy. An electro-
cardiography-gated point resolved single-voxel proton
spectroscopy sequence (TE  32 ms, TR  810 ms)
was used to determine the molecular content of lipids and
water. For reference purposes, LV imaging was carried out
in 4-chamber and short-axis views. The spectroscopic vol-
ume of interest was positioned using these 2 perpendicular
image series in end-systolic phase, so as to lie entirely within
the intraventricular septum. Volume-of-interest dimensions
were 17  15  7 mm3. The septum was chosen as a
ocation sufficiently distant from the Efat compartments to
avoid contamination.
To acquire fully relaxed magnetization, 8 systolic
electrocardiography-gated single-excitation acquisitions
were performed separately in 8 breath holds. Spectra were
analyzed using home-developed software running under an
Interactive Data Language environment (ITT Visual Solu-
tions, Boulder, Colorado). The MTGC was determined by
integrating the frequency domain and expressing the result
as a percentage of the water signal (%TG (triglyceride) 
TG/water  100) (Fig. 1).The intraobserver and interob-
server reproducibility was acceptable, with variation coeffi-
cients of 3.3% and 8.8%, respectively.
Statistical analyses. All statistics were performed using
GraphPad Prism, version 5.00 (GraphPad Software, San
Diego, California). All results are presented as mean  SD
or median (first to third quartiles) when applicable. Com-
parison of baseline and 6-month parameters were performed
using paired t test or Wilcoxon matched-pairs signed-ranks
test when appropriate (each variable normality tested with
the Kolmogorov-Smirnov test). Comparison of patients
with or without SAS was performed using unpaired t test or
ilcoxon test when appropriate. Spearman or Pearson
orrelations when applicable were used to study the rela-
ionships between visceral abdominal fat and EFV or
ercentages of fat losses. Logistic regression analysis was
erformed to evaluate the association between visceral and
fat, adjusted for age and sex. No further adjustment was
done for comparisons between groups. The LV function
parameters were normalized to body surface area as usually
described, to enable more stringent allowance for obesity.
Results
Clinical characteristics. Among the 29 patients included
in the study, 25 morbidly obese patients (6 men, 19
women), underwent BS (19 sleeve gastrectomies, 5 Roux-
en-Y gastric bypasses, and 1 adjustable gastric banding), and
23 patients underwent the 6-month MRI (1 patient was a
dropout, and 1 patient had a post-operative complication(spleen hematoma) (Fig. 1). Their clinical characteristics are
shown in Table 1. Mean age was 41  11 years, and mean
BMI was 43.1  4.5 kg/m2. Eight patients had SAS. No
ifference was found in clinical characteristics between
atients with and without SAS (Online Table 1).
hanges in anthropometric and metabolic variables after BS.
he BS reduced weight significantly from 116  17 kg to
7  13 kg (p  0.0001) and BMI from 43.1  4.5 kg/m2
to 32.3  4.0 kg/m2 (p  0.0001); no difference was
observed in the percentage of excess weight loss, neither for
the type of surgery (p  0.38) nor for sex (p  0.82). After
months of weight loss, as expected, there was a significant
eduction in visceral and subcutaneous fat with a greater loss
f visceral fat (40  19%) than of other fat deposits: total
ubcutaneous fat 28  22%; superficial 29  26%, and
eep 30  31% (Online Appendix, Online Table 2).
fter surgery, antihypertensive treatment could be stopped
or 5 of 8 patients with hypertension, lipid-lowering drugs
or 4 of 10 patients with dyslipidemia, and an oral antidia-
etic drugs or glucagon-like peptide-1 analog for 4 of 5
atients with diabetes. As expected, bariatric surgery in-
uced significant improvement of glycemic parameters and
nsulin resistance (Table 2). High-density lipoprotein cho-
esterol and low-density lipoprotein cholesterol were un-
hanged, and there was a trend toward a reduction in
riglycerides (p  0.05) with a drop in the use of lipid-
owering drugs. In addition, low-grade inflammation and
iver enzyme levels also significantly decreased (Table 2).
hanges in LV function after BS. Six months after BS, a
arked significant decrease in LV mass (118 24 g at baseline
s. 101  18 g, p  0.002) and cardiac output (7.1  1.6 at
baseline vs. 5.4  1.0, p  0.0001) were observed (Fig. 2).
When LV mass was adjusted for body surface area, there was
no difference between before and after BS, whereas cardiac
index remained significantly decreased (p  0.01). The de-
creased LV mass (12  18%) was related to the decreased
Main Clinical Characteristicsof the Studied Population (n  23)Table 1 Main Clinical Characteristicsof the Studied Population (n  23)
Age, yrs 41 11
Male/female 4/19
BMI, kg/m2 43.1 4.5
Excess body weight, kg 49 13
Family history of CAD 8 (35%)
Hypertension 8 (35%)
Diabetes mellitus 6 (26%)
Duration of diabetes, yrs 3 6
OAD treated 6/6
Insulin treated 0/6
GLP-1 analog treated 1/6
Glucose intolerance, OGTT diagnosed 1 (4%)
Dyslipidemia 10 (43%)
Smoker 2 (9%)
Duration of physical activity, h per week 1.7 2.1
Values are mean  SD or n (%).
BMI  body mass index; CAD  coronary artery disease; GLP  glucagon-like peptide; OAD 
oral antidiabetic drugs; OGTT  oral glucose tolerance test.
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October 9, 2012:1381–9 Bariatric Surgery and Cardiac Ectopic Fatpercentage of weight loss (r  0.46, p  0.03), but not to the
lowering of blood pressure (p  NS). Heart rate decreased
slightly from 79  11 beats/min to 72  16 beats/min (p 
.04). Finally, BS led to favorable changes in diastolic
unction, with a 24  36% increase in E/A ratio (p 
.03), and a 17  24% decrease in left atrial dimensions
p  0.02) (Fig. 3).
hanges in cardiac ectopic fat after BS. At baseline, EFV
as strongly correlated with baseline VAF (r  0.61, p 
.002), but not with age or BMI. Visceral abdominal fat and
fat significantly decreased after surgery from 190 83 cm
2
to 107  44 cm2, and from 137  37 ml to 98  25 ml,
espectively; both p  0.0001. Importantly, despite a high
evel at baseline, there was no significant change in MTGC:
Main Changes in Metabolic Serum CharacteristTable 2 Main Changes in Metabolic Serum
Changes in Characteristics At Base
Lipid profile
Total cholesterol, mmol/l 4.6 1
LDL cholesterol, mmol/l 2.9 1
HDL cholesterol, mmol/l 1.23 (1.04–
Triglycerides, mmol/l 1.38 (0.97–
Glucose tolerance
Fasting plasma glucose, mmol/l 5.10 (4.6–6
Fasting plasma insulin, mUI/l 17.3 (11.6–
HOMA-IR 4.62 (3.22–
Fasting adiponectin, g/ml 4 (3–5)
Fasting leptin, ng/ml 102 5
Uric acid, mol/l 319 8
Inflammation biomarkers
High-sensitivity CRP, mg/l 10 (6–15
Fibrinogen, g/l 3.96 (3.51–
PAI-1, UI/ml 30 2
Liver enzymes
ASAT 25 (20–3
ALAT 38 2
GGT 26 (19–3
Values are mean  SD or median (first to third quartiles) when appro
ALAT  alanine transaminase; ASAT  aspartate transaminase;
high-density lipoprotein; HOMA-IR  homeostasis model assessmen
PAI  plasminogen-activator inhibitor.
Figure 2 Effect of Bariatric Surgery
Effect of bariatric surgery on (left) left ventricular (LV) mass and (right) cardiac ou
was observed after bariatric surgery. **p  0.001; ***p  0.0001..03  0.2% at baseline versus 1.1  0.2% after surgery
p  0.85) (Fig. 4). In addition, the loss in EFV was more
imited (27  11%) compared to VAF diminution (40 
19%), and we observed interindividual variability in EFV
loss from 5 to 47% (Fig. 5). We identified 2 types of
patients: a group with a parallel decrease in visceral fat and
Efat, and a group with a lesser decrease in epicardial
compared to visceral fat loss (Fig. 6). Unexpectedly, the
percentage of Efat loss was not correlated to the percentage
of BMI or to subcutaneous fat loss, nor to the percentage of
visceral fat loss (r  0.14, p  0.53), suggesting that the 2
deposits decreased significantly, but in different proportions
according to the patient (p  0.007 for paired t test) (Fig. 5).
The variations in fat deposits were not correlated.
fter Bariatric Surgerycteristics After Bariatric Surgery
6 Months After Surgery p Value
4.7 0.9 NS
2.8 0.8 NS
1.37 (1.05–1.55) NS
1.2 0.4 0.05
4.6 0.7 0.009
4.5 (4.2–4.6) 0.0001
0.76 (0.41–1.05) 0.0004
7.8 4.3 0.004
36 23 0.003
302 65 0.05
4 (2–7) 0.0006
3.62 (3.12–4.01) 0.03
3 (2–9) 0.005
20 (18–24) 0.04
26 8 0.02
15 (11–17) 0.005
C-reactive protein; GGT  gamma glutamyltranspeptidase; HDL 
ulin resistance; LDL  low-density lipoprotein; NS  not significant;
significant decrease in LV mass and cardiac output (paired t test)ics AChara
line
.2
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Bariatric Surgery and Cardiac Ectopic Fat October 9, 2012:1381–9Studying factors participating in this lack of Efat loss, we
alculated the ratio of %EFV loss to %VAF loss to identify
atients with a lesser decrease in epicardial versus visceral fat
oss (ratio 1). We observed that this ratio decreased with
AS (1.34  0.3 vs. 0.52  0.08, p  0.05), suggesting a
lesser decrease in Efat compared to visceral fat in these
patients (Fig. 7). No difference was evidenced for other
complications of obesity such as diabetes or hypertension.
Finally, the percentage of EFV loss did not decrease with
age, sex, or type of surgery.
Discussion
Our study confirms that BS induced a drastic reduction in
biological cardiovascular risk markers, such as inflammatory
and insulin resistance parameters, and improved cardiac
function, particularly diastolic function. We demonstrated
that, by 6 months after BS, EFV was significantly reduced.
Surprisingly, the decrease in Efat was different from that of
isceral fat. We showed that the loss of EFV was reduced in
atients with SAS, despite sustained reduction in weight
nd an improved metabolic profile. Furthermore, no effect
f BS on MTGC was evidenced.
Figure 3 Effect of Bariatric Surgery on E/A Ratio and Surface
Effect of bariatric surgery (left) on early (E) to late (A) peak diastolic transmitral flo
(LA area [paired t test]). A significant decrease in E/A ratio and LA area (paired t t
Figure 4 Change in Cardiac Ectopic Fat, VAF, and Myocardial T
Change in (left) cardiac ectopic fat (epicardial fat volume [EFV]), (middle) visceral
bariatric surgery. A significant decrease in EFV and VAF was found (***p  0.0001),Epicardial fat located on the outer surface of the adven-
itia of the coronary arteries has been linked locally to the
athogenesis of CAD (25). Factors secreted from Efat, such
s free fatty acids and adipokines, can directly affect the
unction of the heart and blood vessels. Patients with CAD
ave been shown to accumulate more Efat than patients
without CAD (26). Studying the factors that can reduce
EFV is therefore essential.
Using 3-T MRI as a gold standard technique to evaluate
cardiac function and EFV, we confirmed that weight loss
can reduce EFV. Indeed, Iacobellis et al. (16) have previ-
ously shown, using echography, that 6 months on a very low
calorie diet induced a 32% reduction in Efat thickness; and
illens et al. (18), in 23 patients with severe obesity,
howed a 24% decrease in Efat thickness 8 months after BS.
owever, because Efat thickness varies at different locations
around the heart (3) and shows considerable interindividual
differences in its distribution, this may limit the use of
echocardiography to measure Efat at 2 different time points.
picardial adipose tissue is a visceral thoracic fat depot
ocated along the coronary arteries and on the surface of the
entricles. It is considered to be a marker for visceral
Area
city (E/A ratio) and (right) on the surface of the left atrium
as observed after bariatric surgery. *p  0.05.
ceride Content 6 Months After Bariatric Surgery
inal fat (VAF), and (right) myocardial triglyceride content 6 months after
s there was no significant change in myocardial triglyceride content (p  0.05).of LA
w velo
est), wrigly
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October 9, 2012:1381–9 Bariatric Surgery and Cardiac Ectopic Fatabdominal adiposity as its volume has been shown to be
highly correlated with that of visceral fat (10). Our work is
the first study to compare the loss of VAF with cardiac
ectopic fat deposits. We observed that the ability of these
fats to decrease was different and that they were not linked,
the change in EFV being less important than that of VAF.
This result was unexpected as both tissues share common
embryological origins (splanchnic mesoderm) and charac-
teristics, such as increased macrophages and inflammatory
cytokines. That is even more surprising, considering that
they have an enhanced rate of lipolysis when compared to
subcutaneous fat deposits, which provide the capability of
releasing lipids rapidly on demand (25), and many studies
have shown that acute caloric restriction produces early
preferential loss of VAF (27). Moreover, we identified that
patients with SAS had impaired EFV loss compared to
Figure 5 Comparison Between VAF and EFV After Bariatric Sur
(A) Correlation between epicardial fat volume (EFV) and visceral abdominal fat (VA
parison of the percentages between EFV loss and VAF loss after bariatric surgery.
decreased differently: the percentage of EFV loss was not correlated to the percen
loss (paired t test) (C).
Figure 6 Differential losses in EFV and VAF From 2 Patients
The 2 examples illustrate the 2 phenotypes identified in the study population. Pat
epicardial fat volume (EFV), whereas Patient #7 is an example of a lesser decreasVAF loss. This finding suggests that Efat is very sensitive to
ntermittent hypoxia, which can be an early initiator of
dipose tissue dysfunction, by inducing a local state of
brosis. It was shown that hypoxia-inducible factor 1alpha
HIF1alpha) over-expression initiates adipose tissue fibro-
is, with an associated increase in local inflammation (28).
urthermore, an interesting study by Divoux et al. (29)
howed that a high level of fibrosis in subcutaneous adipose
issue was a factor of resistance in weight loss and to loss of
at mass after gastric bypass surgery in morbidly obese
atients (29).
We hypothesize that fibrosis may affect Efat deposits and
decrease its capacity to be modulated by weight loss. Several
indirect arguments support this theory: compared with
subcutaneous fat, Efat secretes more activin A, a member of
he transforming growth factor-beta family, which is a
aseline. (B) Correlation between the percentage loss of EFV and VAF. (C) Com-
eline, the 2 fat deposits were strongly correlated (A), whereas after surgery they
f VAF loss (Spearman correlation) (B) and was less important than that of VAF
lost approximately the same quantity of visceral abdominal fat (VAF) and
FV than VAF, suggesting “resistance” to EFV loss.gery
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I collagen (30). It also exerts a profibrotic effect on the liver
and kidney, and is associated with interstitial pulmonary
fibrosis (31). Epicardial fat has been shown to secrete more
inflammatory mediators than subcutaneous fat and to be
infiltrated by inflammatory cells (T cells, macrophages, and
mast cells) (9,11). Accordingly, macrophage-secreted fac-
tors in an inflammatory environment lead to activin A
secretion and to the profibrotic phenotype of human pre-
adipocytes, which share strong phenotypic and biological
similarities with fibroblasts (32). Experimental studies are
ongoing to confirm whether Efat is the site or can induce
fibrosis of neighboring heart structures.
Treatment could also modify EFV loss. Park et al. (33)
showed a significant reduction in Efat thickness with ator-
astatin, and Jonker et al. (34) showed a significant increase
ith pioglitazone. However, no patient in our study was
reated with pioglitazone, and no patients treated with
torvastatin stopped treatment during our study. Snel et al.
35) in a recent paper showed a sustained pericardial fat loss
8 months after a very low calorie diet for insulin-treated
ype 2 diabetes, despite a substantial regain in weight and
isceral fat. This demonstrates that VAF and epicardial or
ericardial fat may vary in response to weight loss or gain.
ll together, these observations suggest that more studies
re needed to investigate the impact of nutritional or
urgical interventions on the variation and redistribution of
ndogenous fat stores. Whether this effect concerns prefer-
ntially epicardial fat over pericardial fat and whether it is
aintained long term after weight and glycemic control
tabilization need to be addressed in further studies.
Although previous studies have shown a beneficial effect
Figure 7 Percentage Loss of EFV to Percentage Loss
of VAF in Patients With and Without SAS
Comparison of the percentage loss of epicardial fat volume (EFV) to the per-
centage loss of visceral abdominal fat (VAF) in patients with and without sleep
apnea syndrome (SAS). The percentage EFV loss to percentage VAF loss ratio
was significantly lower in patients with SAS, indicating that these patients lost
less epicardial fat than visceral fat.f a restrictive diet (for 6 weeks) or endurance exercise onyocardial fat (36–38), this is the first study to demonstrate
o effect of BS on MTGC content. Recent studies by
annukainen et al. (39) seem to confirm these results.
owever, a potential increase in physical activity could not
e avoided in this study and may have affected the myocar-
ial fat in our patients, as previously demonstrated by other
roups (37,40). One hypothesis is that the lack of change in
yocardial fat may be because this ectopic deposit is more
exible than Efat, and is a permanent source of fatty acids to
fuel the myocardium. Baseline values for MTGC were
higher than those found in healthy populations (15,20), so
that we could not conclude that the lack of BS effect on
MTGC was due to MTGC variation in normal range
values. Nevertheless, further studies with larger sample size
are still required to confirm our results.
This study is limited by the modest sample size, the short
follow-up period, and the variability of procedures performed,
which differed in their malabsorption components and may
thus have had a different impact on lipid partitioning after
surgery. Moreover, we did not assess other ectopic fat depots
such as hepatic triglyceride content, which could have been
related to the improvement of biological parameters.
Previous studies have shown that proinflammatory adi-
pokines are reduced in subcutaneous adipose tissue and that
macrophages switch to a less proinflammatory profile after
gastric bypass (41). Whether the reduction in the amount of
Efat after weight loss is associated with changes in adipokine
expression or secretion is still unknown and merits further
evaluation.
Conclusions
For patients with morbid obesity, significant weight loss at 6
months after BS is associated with a significant reduction of
EFV but not with changes in MTGC. It is likely that the
beneficial effects of BS on Efat are at least partially responsible
or the reduced cardiac mortality seen with weight loss.
nterestingly, we found that patients with SAS were “resistant”
o epicardial fat loss. Whether early treatment of SAS can
everse these findings is unknown and needs further study.
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